InspireMD Announces First Patient Enrolled Into New CGuard(TM) CARENET (CARotid Embolic protection study using microNET) Clinical Trial
PR Newswire - Wed Mar 19, 8:00AM CDT
InspireMD, Inc. ("InspireMD" or the "Company"
InspireMD to Present at the 26th Annual ROTH Conference
PR Newswire - Thu Mar 06, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD to Present at the Cowen & Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013
PR Newswire - Wed Feb 26, 3:05PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014
PR Newswire - Tue Feb 18, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD Reports Successful Implantation of the New CGuard(TM) Carotid Embolic System with MicroNet(TM) Technology
PR Newswire - Wed Feb 05, 8:23AM CST
InspireMD, Inc. ("InspireMD" or the "Company"
3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion by 2019
M2 - Mon Jan 27, 9:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rr9nj/3_catalysts_to) has announced the addition of the "3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion" report to their offering. The global coronary stent market is expected to be over $13 billion by 2019, despite the current downward trend in the US, the largest market, and declining selling prices globally. Increasing PCI (percutaneous coronary intervention) procedures triggered by the rising prevalence of CAD (coronary artery disease), novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has remained stagnant for a few years. The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications. The stent market globally and in the developed nations is largely controlled by three players - Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume. This comprehensive, 465 page global strategic business report is authored by a team of sector analysts who used rigorous primary and secondary research and robust analytical models to provide strategic insight and to forecast for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies. Data at global, continents, economic zones, and country level: - Market size of coronary stents in terms - value and volume (2005-2019) for BMS, DES and Bioabsorbables (Bioresorbable - BVS) - Market growth rates (2005-2019) - Average prices of various stents in all the covered geographies (2005-2019) - Number of PCI procedures - Analytical comparison between different continents and economic regions - Market dynamics - market trends, drivers, restrains, issues, competitive landscape - Detailed pipeline and clinical studies - Product approval status - major geographies - Industry consolidation, partnerships, product launches, approvals and recalls - Detailed company profiles of around 70 companies from different levels of value chain Key Topics Covered: 1. Charts & Tables 2. Executive Summary 3. Market at a Glance 4. Introduction to Stents 5. Coronary Stents 6. Types of Stents 7. Approvals 8. Competitive Landscape 9. Clinical Studies 10.Coronary Stents - Market Drivers and Restrains 11.Overview: Market trends 12.Approvals Driving the Growth 13. Market Data 14.Company Profiles 15.Recent Events 16.Appendix 17. Research Methodology 18. Disclaimer Companies Mentioned Include: - Abbott Vascular - Alvimedica Medical Technologies - Arterial Remodeling Technologies - Boston Scientific Corporation - Biosensors International - Biotronik SE & Co.kG - CID S.r.l. - Clearstream Technologies Ltd. - Disa Vascular (Pty) Ltd. - Elixir Medical Corporation - Endocor Gmbh - Essen Technology (Beijing) Co., Ltd - Hexacath - Iberhospitex S.A - InspireMD, Inc. - Japan Stent Technology Co., Ltd. - Kyoto Medical - Lepu Medical Technology Co., Ltd. - Medinol - Medtronic, Inc. - Meril Life Sciences Pvt. Ltd. - Micell Technologies, Inc. - MicroPort Scientific Corporation - Minvasys - OrbusNeich - Relisys Medical Devices Limited - Terumo Medical Corporation - Translumina - Tryton Medical - Vascular Concepts For more information visit http://www.researchandmarkets.com/research/3r...talysts_to
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 22, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
InspireMD to Present at the 24th Annual Oppenheimer & Co. Healthcare Conference in New York City on December 11th
PR Newswire - Tue Dec 03, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
PR Newswire - Mon Dec 02, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD Announces Upcoming Investor Event in Israel
PR Newswire - Tue Nov 19, 8:13AM CST
InspireMD, Inc. ("InspireMD" or the "Company"
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
PR Newswire - Mon Nov 11, 3:01PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD to Report Financial Results for Quarter Ending September 30, 2013 on Monday, November 11, 2013
PR Newswire - Mon Nov 04, 7:00AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD's MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
PR Newswire - Tue Oct 29, 3:23PM CDT
InspireMD, Inc. ("InspireMD" or the "Company"
InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
PR Newswire - Mon Oct 28, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
Empire Asset Management Company initiates coverage on INSPIRE MD with a Buy rating
PR Newswire - Fri Oct 25, 8:14AM CDT
Today Empire Asset Management Company, a FINRA member (CRD 143007), initiated coverage of INSPIRE MD (NYSE MKT: NSPR) with a Buy rating and 12 month price target of $9.00.
InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan
PR Newswire - Thu Oct 24, 8:15AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD Files At-the-Market Offering and Shelf Registration Statement
PR Newswire - Thu Oct 24, 8:08AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
PR Newswire - Wed Oct 23, 1:43PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
PR Newswire - Tue Sep 17, 3:05PM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"